Cargando…
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy
Tumor mutational burden (TMB), a surrogate for tumor neoepitope burden, is used as a pan-tumor biomarker to identify patients who may benefit from anti-program cell death 1 (PD1) immunotherapy, but it is an imperfect biomarker. Multiple additional genomic characteristics are associated with anti-PD1...
Autores principales: | Bigelow, Emma, Saria, Suchi, Piening, Brian, Curti, Brendan, Dowdell, Alexa, Weerasinghe, Roshanthi, Bifulco, Carlo, Urba, Walter, Finkelstein, Noam, Fertig, Elana J, Baras, Alex, Zaidi, Neeha, Jaffee, Elizabeth, Yarchoan, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685115/ https://www.ncbi.nlm.nih.gov/pubmed/36439024 http://dx.doi.org/10.1177/11769351221136081 |
Ejemplares similares
-
Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors
por: Davis-Marcisak, Emily F., et al.
Publicado: (2021) -
Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways
por: Ho, Won Jin, et al.
Publicado: (2021) -
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
por: Huff, Amanda L., et al.
Publicado: (2022) -
Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development
por: Zaidi, Neeha, et al.
Publicado: (2020) -
Actualizing Personalized Healthcare for Women through Connected Data Systems: Breast Cancer Screening and Diagnosis
por: Nelson, Heidi D, et al.
Publicado: (2013)